# REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

> **NCT00485069** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 123 (actual)

## Conditions studied

- Parkinson Disease
- Parkinson's Disease

## Interventions

- **DRUG:** ROP
- **DRUG:** ROP+L-Dopa

## Key facts

- **NCT ID:** NCT00485069
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2010-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485069, "REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00485069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*